NCT05422183 is a Phase 2 clinical trial of Envafolimab in Ovarian Cancer, Epithelial, sponsored by Zhongda Hospital.

Who is sponsoring NCT05422183?

NCT05422183 is sponsored by Zhongda Hospital.

What drugs are being tested in NCT05422183?

Interventions in NCT05422183: Envafolimab, Lenvatinib, VP-16.

What condition does NCT05422183 study?

NCT05422183 studies Ovarian Cancer, Epithelial.

Is NCT05422183 still recruiting?

NCT05422183 is currently status unknown. Last updated 16 June 2022.

Last reviewed 2022-06-16 · How we verify

NCT05422183

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Status unknown Phase 2 Last updated 16 June 2022

What this trial tests

Phase 2 trial testing Envafolimab in Ovarian Cancer, Epithelial in 20 participants. Status unknown.

Timeline

30 June 2022

Primary endpoint
30 December 2022

30 December 2023

Quick facts

Lead sponsor	Zhongda Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	30 June 2022
Primary completion	30 December 2022
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

Envafolimab — full drug profile →
Lenvatinib (LENVATINIB) — full drug profile →
VP-16 — full drug profile →

Conditions studied

Ovarian Cancer, Epithelial — all drugs for Ovarian Cancer, Epithelial →

Sponsor

Zhongda Hospital

Who can join

18 and older, female only, with Ovarian Cancer, Epithelial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer，primary fallopian tube cancer and primary peritoneal carcinoma.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises.
Skorda A, Bay ML, Hautaniemi S, Lahtinen A, et al · · 2022 · cited 24× · PMID 36551745 · DOI 10.3390/cancers14246257
Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
Hu X, Bian C, Zhao X, Yi T. · · 2022 · cited 19× · PMID 36275669 · DOI 10.3389/fimmu.2022.1034903
Immunotherapy in Recurrent Ovarian Cancer.
Chen K, Wang J, Yang M, Deng S, et al · · 2025 · cited 7× · PMID 39857752 · DOI 10.3390/biomedicines13010168
Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide.
Ding B, Yu T, Zheng S, Xu J, et al · · 2025 · PMID 40658469 · DOI 10.1093/oncolo/oyaf210

Verify or expand the search:

Other trials of Envafolimab

Trials testing the same drug.

NCT06959693 — A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients Wit · Phase 2, PHASE3 · not yet recruiting
NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
NCT06618391 — Local Injection and Systemic Therapy in the Treatment of NSCLC. · Phase 2 · not yet recruiting
NCT06663007 — RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure · Phase 1, PHASE2 · recruiting

Other recruiting trials for Ovarian Cancer, Epithelial

Currently open trials in the same condition.

NCT06640348 — Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovari · recruiting
NCT05107674 — A Study of NX-1607 in Adults With Advanced Malignancies · Phase 1 · recruiting

Other Zhongda Hospital trials

Trials by the same sponsor.

NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05422183 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
Last refreshed: 16 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05422183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing